Comparing immune responses to bacterial and viral infections in ICU patients
COMPArative Study of the Consequence on innaTe Immune Response du to Bacterial or Viral Infection in Patients Admitted to Intensive Care Unit
This study is testing how the immune system reacts to bacterial and viral infections in ICU patients by looking at certain blood cells to see if there are differences based on the type of infection.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 38 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Limoges Academic / other |
| Locations | 1 site (Limoges) |
| Trial ID | NCT05671159 on ClinicalTrials.gov |
What this trial studies
This study investigates the immune response of patients admitted to the intensive care unit (ICU) for acute infections caused by either bacteria or viruses. It focuses on the analysis of immature granulocytes (IG) in the blood, which are indicative of immune impairment during these infections. By utilizing flow cytometry, the study aims to characterize the concentration, phenotype, and function of IG based on the type of infection. Additionally, transcriptomic and cytokine analyses will be performed to gain deeper insights into the innate immune response in these patients.
Who should consider this trial
Good fit: Ideal candidates include adult patients admitted to the ICU for less than 24 hours with confirmed bacterial or viral infections.
Not a fit: Patients who are immunocompromised or have ongoing infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of immune responses in critically ill patients, potentially leading to improved treatment strategies for infections.
How similar studies have performed: While the specific approach of this study may be novel, similar studies have shown the importance of analyzing immune responses in critically ill patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Bacterial infection: * Adult patient hospitalized for less than 24 hours in ICU for community documented sepsis * Vasopressor support * SOFA score \> 4 * Viral infection: * Adult patient hospitalized for less than 24 hours in ICU for confirmed viral acute infection. * High flow oxygen, non-invasive or invasive ventilation since less than 24 hours * Moderate to severe ARDS with PaO2/FiO2 \< 200mmHg and a FiO2 ≥ 0.6. Exclusion Criteria: * Bacterial infection: * Antibiotics or hospitalized in ICU in the previous 3 months * Immunocompromized patient * Ongoing acute or chronic viral infection * Viral infection: * Antibiotics or hospitalized in ICU in the previous 3 months * Immunocompromized patient * Current antibiotics * Ongoing chronic viral infection.
Where this trial is running
Limoges
- Limoges University Hospital — Limoges, France (Recruiting)
Study contacts
- Study coordinator: Thomas DAIX, MD
- Email: thomas.daix@chu-limoges.fr
- Phone: 555066983
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.